MRNA Stock Recent News

Moderna, Inc. (NASDAQ:MRNA ) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Corporate Participants Stephen Hoge - President Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren All right, well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.

Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares moved higher after it was disclosed the company insiders have purchased $6 million in shares. According to filings with the Securities and Exchange Commission (SEC), CEO Stephane Bancel purchased 160,314 shares for $5 million.

A German court in Duesseldorf on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna.

The S&P 500 has soared in recent times, delivering two consecutive years of double-digit gains, and investors -- from billionaires to small retail investors -- have piled into some of the biggest winners. I'm talking about technology stocks, and, more specifically, players operating in the high-growth area of artificial intelligence (AI).

BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries.

BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries.

mRESVIA ® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. "The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna.

Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But these aren't the only areas that offer the potential for explosive revenue growth and stock performance.

SHANGHAI , Feb. 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines, today announced that it will hold investor calls to discuss recent developments on its mRNA therapeutic vaccine programs. The English session of the conference call will be held at 9:00 pm on March 6, 2025 Beijing Time (8:00 am U.S. Eastern Time on March 6), and the Mandarin session of the conference call will be held at 9:00 am Beijing Time on March 7, 2025 (8:00 pm U.S. Eastern Time on March 6).

Moderna stock toppled Thursday on reports the Trump administration is considering pulling bird flu vaccine funding. The post Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds appeared first on Investor's Business Daily.